Search
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: SOTYKTU 6 mg film coated tablets, SOTYKTU® 6MG TABLETAS RECUBIERTASChromic chloride
go.drugbank.com/drugs/DB09129ApprovedChromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: M T E 4 Concentrate Inj, Addamel NCategories: Compounds used in a research, industrial, or household settingEnsartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingOrlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalIt was approved by the FDA for use in combination with a reduced-calorie diet in 1999. … [A229928] Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes.
Categories: Miscellaneous GI Drugs, Cytochrome P-450 CYP3A InducersProducts: SLENDER 1, LINADEX®Poa pratensis pollen
go.drugbank.com/drugs/DB10366ApprovedPoa pratensis pollen is the pollen of the Poa pratensis plant. Poa pratensis pollen is mainly used in allergenic testing.
Mixtures: ORALAIR 100 IR + 300 IR Sublingualtabletten, ORALAIR 100 IR + 300 IR SublingualtablettenAstemizole
go.drugbank.com/drugs/DB00637ApprovedWithdrawnAstemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. … It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice.
Mixtures: PAX DIA, CONGESGRIP POLVO DIACategories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexRespiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigational[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380] … It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with
Synonyms: RSVPreF3 OA, RSVPreF3 OA vaccineDrometrizole trisiloxane
go.drugbank.com/drugs/DB11585ApprovedDespite being used elsewhere in the world with relatively few reports of adverse reactions, the FDA continues to cite that the existing scientific record is not sufficient to establish the compound as … The compound is a lipophilic benzotriazole derivative marketed as Meroxyl XL by L'Oreal, although sunscreens with drometrizole trisiloxane are currently only approved for use in the EU, Canada, Australia
Mixtures: Anthelios XL Melt-IN Cream, Garnier Ombrelle SPF 30 UVA UVB Kids Wet N Protect Sunscreen Protection Even on Wet Skin Hypoallergenic Water/sweat resistant 80 minutes Quick AbsorptionCategories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-RingLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Categories: Dopamine D2 Receptor Antagonists, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: LURAP® 40, LURAP ® 80Moxidectin
go.drugbank.com/drugs/DB11431ApprovedInvestigationalVet approvedIt was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of the milbemycin class. … Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23.
Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsCategories: Compounds used in a research, industrial, or household setting